跳至主要内容
临床试验/NCT05581225
NCT05581225进行中(未招募)不适用

Prediction of Progression of Retinal Ischemia in Diabetes

Association for Innovation and Biomedical Research on Light and Image1 个研究点 分布在 1 个国家目标入组 62 人开始时间: 2022年12月2日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
62
试验地点
1
主要终点
One and 2-steps change on ETDRS severity level (using standard 7-fields CFP acquisitions at 30º and in Wide-field 100º acquisitions).

研究概览

简要总结

Diabetes Mellitus (DM) is a major public health problem with significant socioeconomic implications due to its increased prevalence. Diabetic retinopathy (DR) is the most frequent complication in DM patients and remains the leading cause of legal blindness in working-age populations (Yau et al., 2012). Differentiating patients with higher vs low risk of progression to vision-threatening complications is of paramount importance for an efficient managing of the disease to prevent vision disability.

PREDICTION is a longitudinal prospective clinical study in DMT2 patients with a higher risk of progression to explore possible imaging, functional and systemic biomarkers of progression, using non-invasive methods, commonly applied in the clinical practice. Investigating the retinal vascular network (vessel density metrics with Optical Coherence Tomography Angiography) will allow a better understanding of the evolution of capillary closure and ischemia, two main risk factors for DR worsening.

详细描述

Patients with Mild to Severe NPDR (ETDRS DRSS 43-53) often progress to PDR and/or CI-DME (ETDRS Report). However, it is unclear which patients in this group are likely to progress. Previous studies have shown that diabetic macular ischemia (DMI) is a risk factor for progression of DR. This study aims to correlate baseline OCTA metrics with visual function and identify risk factors for progression from NPDR to PDR and/or CI-DME.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
35 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • DM type 2 according to 1985 WHO criteria.
  • Age between 35 and 80 years.
  • BCVA ≥ 75 letters (20 /32).
  • Refraction with a spherical equivalent less than 5 Diopters.
  • NPDR levels 43, 47 or 53 (based on the ETDRS criteria - 7 fields CFP).

排除标准

  • Cataract or other eye disease that may interfere with fundus examinations.
  • HBA1C ≥ 12%
  • Any eye surgery within a period of 6-months before the inclusion visit date.
  • Other retinal vascular disease.
  • Previous laser or intravitreal injection treatment.
  • Dilatation of the pupil < 5 mm.

结局指标

主要结局

One and 2-steps change on ETDRS severity level (using standard 7-fields CFP acquisitions at 30º and in Wide-field 100º acquisitions).

时间窗: 48 months

Identify and characterize the progression of retinal microvascular changes (vascular occlusion) occurring in eyes with moderate to severe NPDR (ETDRS severity levels 43, 47 or 53).

Changes in Vessel density (VD) metrics (skeletonized VD, binarized VD (PD), considering macular region and midperiphery.

时间窗: 48 months

Explore new OCTA vascular metrics and identify which can be used as imaging biomarkers to better identify DR progression (skeletonized VD, binarized VD (PD).

Changes in geometric perfusion deficits (GPD) on the superficial and deep retinal vascular layers on SS-OCTA, considering macular region and midperiphery.

时间窗: 48 months

Explore new OCTA vascular metrics and identify which can be used as imaging biomarkers to better identify DR progression geometric perfusion deficits (GPD) using 3mm x 3mm and wide-field 15mm x 15mm OCTA acquisitions.

次要结局

  • Changes in mean luminous sensitivity in dB, evaluated by Microperimetry.(48 months)
  • Changes in BCVA (ETDRS letters chart).(48 months)
  • Changes in FAZ area on OCTA(48 months)
  • Changes in circularity on OCTA.(48 months)
  • Changes in GCL + IPL thickness evaluated by SD-OCT.(48 months)
  • Changes in CRT and layer by layer thickness evaluated by SD-OCT.(48 months)
  • Changes in perimeter on OCTA.(48 months)

研究者

发起方
Association for Innovation and Biomedical Research on Light and Image
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Prediction of Progression of Retinal Ischemia in... | 临床试验